Phagocyte-specific calcium-binding S100 proteins as clinical laboratory markers of inflammation

2004 ◽  
Vol 344 (1-2) ◽  
pp. 37-51 ◽  
Author(s):  
Dirk Foell ◽  
Michael Frosch ◽  
Clemens Sorg ◽  
Johannes Roth
Keyword(s):  
Calcium Binding ◽  
Clinical Laboratory ◽  
S100 Proteins ◽  
Markers Of Inflammation ◽  
Laboratory Markers

scholarly journals C-reactive protein and procalcitonin - laboratory markers of degrees of severity and complications of an acute necrotic pancreatitis

2020 ◽  
Vol 87 (3-4) ◽  
pp. 14-17
Author(s):  
O. V. Rotar ◽  
I. V. Khomiak ◽  
V. I. Rotar ◽  
A. I. Khomiak ◽  
S. I. Railianu
Keyword(s):  
Septic Shock ◽  
Protein Concentration ◽  
Inflammatory Process ◽  
Clinical Laboratory ◽  
C Reactive Protein ◽  
Septic Complications ◽  
Reactive Protein ◽  
Laboratory Markers ◽  
Necrotic Pancreatitis ◽  
Degrees Of Severity

Objective. To conduct comparative estimation of efficacy of C-reactive protein and procalcitonin as laboratory markers for stratification of the patients severity state suffering an acute necrotic pancreatitis. Materials and methods. Prospective cohort investigation, including 151 patients with an acute necrotic pancreatitis, was conducted. Clinical, laboratory and bacteriological investigations were accomplished. The levels of C-reactive protein and procalcitonin were determined in the blood plasm. Results. The necrotic accumulations infectioning was diagnosed in 89 (58.9%) patients: local purulent complications - in 27, sepsis - in 33,septic shock - in 29. In 62 patients with sterile pancreonecrosis a C-reactive protein concentration have raised from (5.6 ± 0.89) to (206 ± 29) mg/l (p˂0.001). Development of purulent-septic complications was accompanied by significant and trustworthy (p<0.01) elevation of procalcitonin concentration: in the patients with sepsis - up to (5.05 ± 0.92) ng/ml, in the patients with septic shock - up to (7.25 ± 2.15) ng/ml. Conclusion. Simultaneous measurement of levels of C-reactive protein and procalcitonin in the blood plasm in patients, suffering acute necrotic pancreatitis, gives permission to determine the inflammatory process character and stratify the disease severity in its early terms.

scholarly journals MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN: DIAGNOSTIC MARKERS AND FEATURES OF PHARMACOTHERAPY

2021 ◽  
Vol 17 (1) ◽  
pp. 24-28
Author(s):  
M.V. Кhaitovych ◽  
L.M. Voroniuk ◽  
G.Yu. Borisova ◽  
N.V. Diudenko ◽  
N.M. Miagka
Keyword(s):  
Distress Syndrome ◽  
The United States ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Markers Of Inflammation ◽  
Laboratory Markers ◽  
Mucous Membranes ◽  
Coronavirus Infection ◽  
Polymerase Chain ◽  
Inflammatory Syndrome

Relevance. In 2020, children were hospitalized with fever and multisystem inflammation throughout the world during the COVID-19 pandemic. In the United States, this condition is called MIS-C (Multisystem Inflammatory Syndrome in Children). This syndrome is thought to be similar to the severe course of COVID-19 in adults (cytokine storm). The objective of the work is to evaluate the features of the course and pharmacotherapy of multisystem inflammatory syndrome in children. Materials and methods. The study included 17 children (10 boys and 7 girls) aged 3-16 years (on average – 9.5±3.4 years). Diagnosis of coronavirus infection was performed by polymerase chain reaction with real-time detection, determined the level of immunoglobulins M and G before coronavirus infection. Results. The duration of fever in patients was 5-21 days (average 8.1±4.0 days), the duration of inpatient treatment – 7-35 days (average 15.7±7.0 days). Blood albumin levels were reduced in 53.8% of children; the level of fibrinogen was increased in 88.2% of children, the level of C-reactive protein, ferritin, and D-dimer – in all patients. 15 (88.2%) children had pathology of the digestive system, 13 (76.5%) – cardiovascular system (7 children were diagnosed with carditis, 2 – dilation of coronary arteries, 7 – cardiac arrhythmia). Acute respiratory distress -syndrome was found in a 13-year-old girl, shock - in an 11-year-old boy, 11 children (64.7%) were diagnosed with the pathology of the respiratory system (pleurisy, pneumonia), skin and mucous membranes, and 4 children (23.5%) there were manifestations of central nervous system disorders (meningism, decreased reflexes, ataxia), in 2 (11.8%) – renal failure. On average, each patient had lesions of 3.9 ±1.2 systems. Conclusions. MIS-C was manifested by prolonged fever, high levels of laboratory markers of inflammation, hypoalbuminemia, hypercoagulation, often – pathological manifestations of the cardiovascular, digestive, respiratory systems, skin, and mucous membranes. The treatment included intravenous immunoglobulin, steroids, anticoagulant, and antibacterial therapy and was effective.

scholarly journals Venous tromboembolic complications in stroke

2018 ◽  
pp. 70-77
Author(s):  
Екатерина Владимировна Силина ◽  
Е.Н. Кабаева ◽  
В.А. Ступин ◽  
А.А. Тяжельников ◽  
Т.Г. Синельникова ◽  
...  
Keyword(s):  
Pulmonary Embolism ◽  
Hemorrhagic Stroke ◽  
Clinical Laboratory ◽  
Disease Onset ◽  
Test Results ◽  
Thromboembolic Complications ◽  
Severe Stroke ◽  
Laboratory Markers ◽  
Venous Thromboembolic Events ◽  
Venous Thromboembolic

Актуальность работы обусловлена поиском путей улучшения результатов лечения больных инсультом. Цель исследования: выявить критерии прогноза риска развития венозных тромбозов, а также ключевые звенья патогенеза тромбоэмболических осложнений у пациентов с острым инсультом. Материалы и методы: в проспективное исследование включено 145 больных с инсультом (104 с ишемическим (ИИ) и 41 с геморрагическим (ГИ)), госпитализированных в отделение нейрореанимации в период 3,5-24 часа от начала заболевания и имеющих на момент включения в исследование различную степень депрессии сознания (тяжелая степень инсульта). Пациентам проводилась терапия в соответствии со стандартами оказания медицинской помощи, согласно которым всем пациентам назначали антикоагулянтную терапию (АКТ). Выполняемый в динамике стандартный клинико-диагностический и лабораторный мониторинг был дополнен тестом «Тромбодинамика». Результаты: у 95% пациентов с инсультом зарегистрированы различные факторы риска венозных тромбоэмболических осложнений (ВТЭО). Тромбоэмболия легочной артерии (ТЭЛА) развилась в 24% случаев, преимущественно на 2-3 неделе, в среднем через 6 дней после отмены АКТ. Описана динамика и признаки дисбаланса в системе гемостаза у больных инсультом, нараставшие после отмены АКТ. Показано, что стандартные методы исследования системы гемостаза по сравнению с прямым методом менее информативны для выявления ВТЭО и оценки эффективности АКТ. Вероятность развития ВТЭО прямо пропорциональна скорости смены состояния гиперкоагуляции состоянием гипокоагуляции. При этом состояние фоновой гиперкоагуляции не коррелирует с развитием ВТЭО. Корреляционный анализ изменений в системе гемостаза с динамикой клинико-лабораторных маркеров у больных с тяжелым инсультом выявил закономерные изменения показателей коагуляционного гемостаза в условиях реализации разных схем стандартной АКТ. Эти схемы были сопоставимы по содержанию при развитии как ВТЭО и ТЭЛА, так и геморрагических осложнений. Вывод: К больным инсультом необходим персонализированный подход при динамическом мониторировании гемостаза и назначении антикоагулянтной терапии. This work was warranted by the need to improve results in the treatment of stroke. The aim of this study was to identify criteria for predicting the risk of venous thrombosis and to elucidate the pathogenesis of thromboembolic complications in patients with acute stroke. Materials and methods. This prospective study included 145 patients (104 patients with ischemic stroke and 41 patients (28.3%) with hemorrhagic stroke). All patients were hospitalized to the neuroresuscitation unit within 3.5 to 24 hours of the disease onset at different stages of consciousness impairment. The patients received anticoagulant therapy (ACT) according to current healthcare standards. Standard clinical diagnostic and laboratory monitoring was supplemented with a Thrombodynamics test. Results. Risk factors for venous thromboembolic events (VTE) were observed in 95% of patients. Pulmonary embolism developed in 24% of cases mostly during weeks 2-3, generally at 6 days of ACT withdrawal. Hemostatic changes and disbalance progressed after the ACT withdrawal. Standard methods of studying hemostasis were shown to be less informative in detecting VTE and evaluating ACT efficacy than the thermodynamics method. The probability of VTE was directly proportional to the velocity of hypercoagulation transformation into hypocoagulation. In this process, the background hypocoagulation was not correlated with the development of VTE. Analysis of correlations of hemostasis changes with changes in clinical-laboratory markers identified relationships of changes in coagulation hemostasis with different standard ACT programs. VTE, pulmonary embolism, and hemorrhagic complications developed in association with administration of comparable ACT programs to patients with severe stroke.

S100A13 and S100A6 exhibit distinct translocation pathways in endothelial cells

2002 ◽  
Vol 115 (15) ◽  
pp. 3149-3158 ◽  
Author(s):  
Hsiao-Ling Hsieh ◽  
Beat W. Schäfer ◽  
Jos A. Cox ◽  
Claus W. Heizmann
Keyword(s):  
Endothelial Cells ◽  
Calcium Binding ◽  
Protein Translocation ◽  
S100 Proteins ◽  
Cellular Functions ◽  
Specific Expression ◽  
Binding Domains ◽  
Cellular Environment ◽  
Ef Hands ◽  
Physiological Tasks

S100 proteins have attracted great interest in recent years because of their cell- and tissue-specific expression and association with various human pathologies. Most S100 proteins are small acidic proteins with calcium-binding domains — the EF hands. It is thought that this group of proteins carry out their cellular functions by interacting with specific target proteins, an interaction that is mainly dependent on exposure of hydrophobic patches, which result from calcium binding. S100A13, one of the most recently identified members of the S100 family, is expressed in various tissues. Interestingly,hydrophobic exposure was not observed upon calcium binding to S100A13 even though the dimeric form displays two high- and two low- affinity sites for calcium. Here, we followed the translocation of S100A13 in response to an increase in intracellular calcium levels, as protein translocation has been implicated in assembly of signaling complexes and signaling cascades, and several other S100 proteins are involved in such events. Translocation of S100A13 was observed in endothelial cells in response to angiotensin II, and the process was dependent on the classic Golgi-ER pathway. By contrast, S100A6 translocation was found to be distinct and dependent on actin-stress fibers. These experiments suggest that different S100 proteins utilize distinct translocation pathways, which might lead them to certain subcellular compartments in order to perform their physiological tasks in the same cellular environment.

scholarly journals A right atrial myxoma presenting with misleading features of acalculous cholecystitis

2020 ◽  
Vol 2020 (2) ◽  
Author(s):  
Ioannis G Lempesis ◽  
Anna Naxaki ◽  
Eirini Koukoufiki ◽  
Ioanna Karagkouni ◽  
Amalia Tzanatou ◽  
...  
Keyword(s):  
Clinical Laboratory ◽  
Epigastric Pain ◽  
Acalculous Cholecystitis ◽  
Gallbladder Wall ◽  
Atrial Myxoma ◽  
Right Atrial ◽  
Imaging Findings ◽  
Markers Of Inflammation ◽  
Upper Abdominal ◽  
The Right

Abstract Diffuse thickening, a layered appearance of the gallbladder wall and the accumulation of surrounding fluid are considered as sensitive and relatively specific imaging findings of gallbladder inflammation. In the absence of gallstones, the diagnosis of acalculous cholecystitis can be further supported by the presence of fever, epigastric pain, right upper abdominal quadrant (RUQ) tenderness on inspiration and elevated markers of inflammation. In this report, we describe a 35-year-old schoolteacher who presented with all of the above clinical, laboratory and imaging findings that were eventually attributed to gallbladder oedema and liver congestion (abdominal imaging and RUQ tenderness) caused by an atrial myxoma interfering, with the atrioventricular circulation of the right heart and causing constitutional manifestations (fever and elevated markers of inflammation).

scholarly journals Role of S100 Proteins in Colorectal Carcinogenesis

2016 ◽  
Vol 2016 ◽  
pp. 1-7 ◽  
Author(s):  
Paula Moravkova ◽  
Darina Kohoutova ◽  
Stanislav Rejchrt ◽  
Jiri Cyrany ◽  
Jan Bures
Keyword(s):  
Calcium Binding ◽  
Colorectal Neoplasia ◽  
Serum Levels ◽  
S100 Proteins ◽  
Colorectal Carcinogenesis ◽  
Invasion And Migration ◽  
Common Cancer ◽  
The Family ◽  
And Migration

The family of S100 proteins represents 25 relatively small (9–13 kD) calcium binding proteins. These proteins possess a broad spectrum of important intracellular and extracellular functions. Colorectal cancer is the third most common cancer in men (after lung and prostate cancer) and the second most frequent cancer in women (after breast cancer) worldwide. S100 proteins are involved in the colorectal carcinogenesis through different mechanisms: they enable proliferation, invasion, and migration of the tumour cells; furthermore, S100 proteins increase angiogenesis and activate NF-κβsignaling pathway, which plays a key role in the molecular pathogenesis especially of colitis-associated carcinoma. The expression of S100 proteins in the cancerous tissue and serum levels of S100 proteins might be used as a precise diagnostic and prognostic marker in patients with suspected or already diagnosed colorectal neoplasia. Possibly, in the future, S100 proteins will be a therapeutic target for tailored anticancer therapy.

scholarly journals Finding the Right Index for Inflammatory Bowel Disease

1995 ◽  
Vol 9 (7) ◽  
pp. 397-400
Author(s):  
E Jan Irvine
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Subjective Symptoms ◽  
Markers Of Inflammation ◽  
Laboratory Markers ◽  
Study Population ◽  
Inflammatory Bowel ◽  
The Right ◽  
Activity Indices ◽  
The Ideal

Several activity indices have been developed to assess the efficacy of new therapies for inflammatory bowel disease. The ideal index should be simple to administer and quantitative. It should be a composite of subjective symptoms, objective findings and laboratory markers of inflammation. Any newly developed indices should be assessed for validity, reliability and responsiveness before application in clinical trials. Obstacles to standardizing disease activity relate to the heterogeneity of disease manifestations, the characteristics of the study population, the therapy being tested, the investigators' preference for which index to apply and the attributes of the index. Examples of available indices are identified, some of their limitations are discussed, and guidelines for how to select an index for a clinical trial are outlined.

Sign in / Sign up

Export Citation Format

Share Document